Table 2 Identification of antibodies to high risk human papilloma viruses in prostate cancer. Case control serological studies with normal sera as controls
From: Evidence for a causal role by human papillomaviruses in prostate cancer – a systematic review
Study | Country | Prostate cancer | Controls | Main HPV types | P value |
|---|---|---|---|---|---|
Dillner 1998 [52] | Finland | 21/165 13% | 36/290 12% | 16,18,33 | 0.865 ns |
Hisada 2000 [53] | US | 20/48 42% | 19/63 30% | 16 | 0.253 ns |
Hayes 2000 [54] | US | 19/276 7% | 15/295 5% | 16 | 0.393 ns |
Rosenblatt 2003 [55] | US | 81/642 13% | 64/570 11% | 16,18 | 0.347 ns |
Adami 2003 [56] | Sweden | 69/238 29% | 48/210 23% | 16,18,33 | 0.212 ns |
Korodi 2005 [57] | Sweden | 107/799 13% | 363/2596 14% | 16,18,33 | 0.482 ns |
Sutcliffe 2007 [58] | US | 107/584 18% | 114/577 20% | 16,18,33 | 0.696 ns |
Sitas 2007 [59] | South Africa | 139/205 68% | 390/673 58% | 16 | 0.001 s |
Huang 2008 [60] | US | 154/868 18% | 310/1283 24% | 16,18 | −0.002 s |
Dennis 2009 [61] | US | 50/267 19% | 45/267 17% | 0.637 ns | |
Sutcliffe 2010 [62] | US | 23/616 4% | 22/616 4% | 16,18,31 | 0.686 ns |
Chen 2011 [12] | Australia | 29/53 55% | 41/104 39% | 16,18,31,33,52,58 | 0.131 ns |
Hrbacek 2011 [63] | Czech | 167/316 53% | 69/101 68% | 16,18,31,33 | −0.161 ns |
Tachezy 2012 [28] | Czech | 14/50 28% | 37/173 22% | 16,18,31,33 | 0.445 ns |
Zhao 2017 [64] | China | 48/75 64% | 14/80 17.5% | 16 | 0.001 s |